{"id":"W4282981679","doi":"10.1158/1538-7445.am2022-ct185","title":"Abstract CT185: A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Familial adenomatous polyposis; Internal medicine; Cmin; Gastroenterology; Nuclear medicine; Cancer; Surgery; Pharmacokinetics; Cmax; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005395917,0.0009924471,0.0008196509,0.0003650864,0.0003078223,0.0005606301,0.0005336575,0.0005398567,0.003637272],"category_scores_gemma":[0.0003381689,0.000322269,0.0005582503,0.0003084248,0.0004124697,0.0003704466,0.0001994787,0.002041919,0.0005913659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009701673,"about_ca_system_score_gemma":0.001417881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00135674,"about_ca_topic_score_gemma":0.003313323,"domain_scores_codex":[0.9998462,0.00005803642,0.00000933825,0.00002409155,0.00002630549,0.00003595167],"domain_scores_gemma":[0.9998079,0.00002180616,0.00003807167,0.00001232964,0.00001514187,0.0001048668],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.367939,0.08729086,0.01486254,0.001684544,0.00146044,0.0008606403,0.0004961788,0.008470399,0.2923891,0.0010656,0.01581022,0.2076705],"study_design_scores_gemma":[0.3003623,0.6240845,0.0261561,0.00009227661,0.0005875495,0.0009973624,0.0001106175,0.003368967,0.0330734,0.0002910107,0.01081858,0.00005729553],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927478,0.001317123,0.0006191846,0.0002613402,0.00006248725,0.001463106,0.001117905,0.0001305476,0.002280525],"genre_scores_gemma":[0.9905182,0.0009470008,0.001512077,0.0004280689,0.00005686808,0.001210259,0.002006409,0.00002107049,0.003300093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003637272,"threshold_uncertainty_score":0.01216793,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06401263804924762,"score_gpt":0.413709845570424,"score_spread":0.3496972075211764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}